Indaptus Q2 net loss narrows as costs fall
Indaptus Q2 net loss narrows as costs fall
Overview
U.S. immunotherapy biotech's Q2 net loss narrowed, driven by lower clinical and payroll costs
Company discontinued Decoy20 clinical study and has no active clinical development programs
Liquidity position improved after $12 mln private placement completed in June 2026
Outlook
Company has discontinued Decoy20 clinical development and is evaluating strategic alternatives for its operations
Indaptus says future activities will depend on scientific validation, market opportunities, and available resources
Result Drivers
LOWER CLINICAL COSTS - Decrease in research and development expenses mainly due to reduced clinical costs for Decoy20 and lower payroll after headcount and salary cuts
REDUCED ADMINISTRATIVE EXPENSES - General and administrative costs declined due to lower payroll and changes in public-company costs during management transition
Company press release: ID:nGNX4fYT1z
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.02 |
|
Reuters Recommended Reads
Aug 11 - Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aug 11 - TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)